1. Medtech Insight
  2. >>Device Area

Exec Chat: How Glooko Plans To Ride Digital Health Care Wave To Profitability

 
• By Marion Webb

In an interview with Medtech Insight, Glooko CEO Russ Johannesson outlines the company’s growth opportunities, expansion plans beyond diabetes and financing plans.

online doctor

The skyrocketing demand for telemedicine and expansion of reimbursement for telehealth visits due to COVID-19 is likely going to shift the paradigm for diabetes care delivery into the future, setting up diabetes software company Glooko, Inc. for continued growth.

When the first shelter-in-place regulations kept diabetes patients from seeing their doctors in the office due to the pandemic, the Mountain View, CA-based company announced it would offer its remote...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.